GlobeImmune resumes Louisville manufacturing
LOUISVILLE — After selling to California-based NantCell Inc., GlobeImmune is restarting operations at its Louisville facility.
The company will be manufacturing at its Louisville facility to support clinical trials for products targeting certain cancers and tumors.
NantCell purchased a controlling interest of GlobeImmune in March for more than $2 million.
SPONSORED CONTENT
How dispatchable resources enable the clean energy transition
Platte River must prepare for the retirement of 431 megawatts (MW) of dispatchable, coal-fired generation by the end of the decade and address more frequent extreme weather events that can bring dark calms (periods when there is no sun or wind).
LOUISVILLE — After selling to California-based NantCell Inc., GlobeImmune is restarting operations at its Louisville facility.
The company will be manufacturing at its Louisville facility to support clinical trials for products targeting certain cancers and tumors.
NantCell purchased a controlling interest of GlobeImmune in March for more than $2 million.
…
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
